Webb PM, Jordan SJ. Global epidemiology of epithelial ovarian cancer. Nat Rev Clin Oncol. 2024;21(5):389–400.

PubMed  Google Scholar 

Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12–49.

PubMed  Google Scholar 

Veneziani AC, Gonzalez-Ochoa E, Alqaisi H, Madariaga A, Bhat G, Rouzbahman M, et al. Heterogeneity and treatment landscape of ovarian carcinoma. Nat Rev Clin Oncol. 2023;20(12):820–42.

PubMed  Google Scholar 

Konstantinopoulos PA, Matulonis UA. Clinical and translational advances in ovarian cancer therapy. Nat Cancer. 2023;4(9):1239–57.

PubMed  Google Scholar 

Tossetta G, Inversetti A. Ovarian cancer: advances in pathophysiology and therapies. Int J Mol Sci. 2023;24(10):8930. https://doi.org/10.3390/ijms24108930.

PubMed  PubMed Central  Google Scholar 

Morgan RD, Clamp AR, Barnes BM, Timms K, Schlecht H, Yarram-Smith L, et al. Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study. Int J Gynecol Cancer. 2023;33(8):1253–9.

PubMed  Google Scholar 

Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D’Andrea AD. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2015;5(11):1137–54.

CAS  PubMed  PubMed Central  Google Scholar 

Feng Z, Shao D, Cai Y, Bi R, Ju X, Chen D, et al. Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma. J Ovarian Res. 2023;16(1):53.

CAS  PubMed  PubMed Central  Google Scholar 

Wang L, Wang X, Zhu X, Zhong L, Jiang Q, Wang Y, et al. Drug resistance in ovarian cancer: from mechanism to clinical trial. Mol Cancer. 2024;23(1):66.

CAS  PubMed  PubMed Central  Google Scholar 

Bi R, Chen L, Huang M, Qiao Z, Li Z, Fan G, et al. Emerging strategies to overcome PARP inhibitors’ resistance in ovarian cancer. Biochimica et Biophysica Acta (BBA). 2024;1879(6): 189221.

CAS  Google Scholar 

Kim YN, Shim Y, Seo J, Choi Z, Lee YJ, Shin S, et al. Investigation of PARP inhibitor resistance based on serially collected circulating tumor DNA in patients with BRCA-mutated ovarian cancer. Clin Cancer Res. 2023;29(14):2725–34.

CAS  PubMed  Google Scholar 

Ethier JL, Fuh KC, Arend R, Konecny GE, Konstantinopoulos PA, Odunsi K, et al. State of the biomarker science in ovarian cancer: A National cancer Institute clinical trials planning meeting report. JCO Precis Oncol. 2022;6:e2200355.

PubMed  PubMed Central  Google Scholar 

Zhao Q, Bai L, Tan Y, Qie M. Limitations of homologous recombination status testing and poly (ADP-ribose) polymerase inhibitor treatment in the current management of ovarian cancer. Front Oncol. 2024;14: 1435029.

CAS  PubMed  PubMed Central  Google Scholar 

O’Malley DM, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from Rucaparib maintenance treatment for high-grade ovarian carcinoma. Gynecol Oncol. 2022;167(3):404–13.

PubMed  PubMed Central  Google Scholar 

Schouten PC, Schmidt S, Becker K, Thiele H, Nurnberg P, Richters L, et al. Olaparib addition to maintenance bevacizumab therapy in ovarian carcinoma with BRCA-like genomic aberrations. JAMA Netw Open. 2024;7(4): e245552.

PubMed  PubMed Central  Google Scholar 

Swisher EM, Kwan TT, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, et al. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nat Commun. 2021;12(1):2487.

CAS  PubMed  PubMed Central  Google Scholar 

Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75–87.

CAS  PubMed  Google Scholar 

Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI, et al. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun. 2018;9(1):3970.

PubMed  PubMed Central  Google Scholar 

Guffanti F, Mengoli I, Damia G. Current HRD assays in ovarian cancer: differences, pitfalls, limitations, and novel approaches. Front Oncol. 2024;14: 1405361.

CAS  PubMed  PubMed Central  Google Scholar 

Galland L, Roussot N, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, et al. Clinical utility of genomic tests evaluating homologous recombination repair deficiency (HRD) for treatment decisions in early and metastatic breast cancer. Cancers (Basel). 2023;15(4):1299. https://doi.org/10.3390/cancers15041299.

PubMed  Google Scholar 

Guffanti F, Mengoli I, Alvisi MF, Dellavedova G, Giavazzi R, Fruscio R, et al. BRCA1 foci test as a predictive biomarker of Olaparib response in ovarian cancer patient-derived xenograft models. Front Pharmacol. 2024;15:1390116.

CAS  PubMed  PubMed Central  Google Scholar 

Pellegrino B, Capoluongo ED, Bagnoli M, Arenare L, Califano D, Scambia G, et al. Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trial. ESMO Open. 2025;10(1):104091.

CAS  PubMed  PubMed Central  Google Scholar 

Capoluongo ED, Pellegrino B, Arenare L, Califano D, Scambia G, Beltrame L, et al. Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial. ESMO Open. 2022;7(5):100585.

CAS  PubMed  PubMed Central  Google Scholar 

Kim YN, Kim K, Joung JG, Kim SW, Kim S, Lee JY, et al. RAD51 as an immunohistochemistry-based marker of poly(ADP-ribose) polymerase inhibitor resistance in ovarian cancer. Front Oncol. 2024;14: 1351778.

CAS  PubMed  PubMed Central  Google Scholar 

Meijer TG, Nguyen L, Van Hoeck A, Sieuwerts AM, Verkaik NS, Ladan MM, et al. Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests. Oncogene. 2022;41(26):3498–506.

CAS  PubMed  PubMed Central  Google Scholar 

van Wijk LM, Vermeulen S, Meijers M, van Diest MF, Ter Haar NT, de Jonge MM, et al. The RECAP test rapidly and reliably identifies homologous recombination-deficient ovarian carcinomas. Cancers (Basel). 2020;12(10):2805. https://doi.org/10.3390/cancers12102805.

PubMed  Google Scholar 

Thorel L, Elie N, Morice PM, Weiswald LB, Florent R, Perreard M, et al. Automated scoring to assess RAD51-mediated homologous recombination in ovarian patient-derived tumor organoids. Lab Invest. 2025;105(4): 104097.

PubMed  Google Scholar 

Fuh K, Mullen M, Blachut B, Stover E, Konstantinopoulos P, Liu J, et al. Homologous recombination deficiency real-time clinical assays, ready or not? Gynecol Oncol. 2020;159(3):877–86.

CAS  PubMed  Google Scholar 

Maya-Mendoza A, Moudry P, Merchut-Maya JM, Lee M, Strauss R, Bartek J. High speed of fork progression induces DNA replication stress and genomic instability. Nature. 2018;559(7713):279–84.

CAS  PubMed  Google Scholar 

Chiang YC, Lin PH, Cheng WF. Homologous recombination deficiency assays in epithelial ovarian cancer: current status and future direction. Front Oncol. 2021;11: 675972.

CAS  PubMed  PubMed Central  Google Scholar 

Sheta R, Bachvarova M, Plante M, Renaud MC, Sebastianelli A, Gregoire J, et al. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy. J Transl Med. 2020;18(1):439.

CAS  PubMed  PubMed Central  Google Scholar 

Morice PM, Coquan E, Weiswald LB, Lambert B, Vaur D, Poulain L. Identifying patients eligible for PARP inhibitor treatment: from NGS-based tests to 3D functional assays. Br J Cancer. 2021;125(1):7–14.

CAS  PubMed  PubMed Central  Google Scholar 

Lheureux S, Prokopec SD, Oldfield LE, Gonzalez-Ochoa E, Bruce JP, Wong D, et al. Identifying mechanisms of resistance by circulating tumor DNA in EVOLVE, a phase II trial of cediranib plus Olaparib for ovarian cancer at time of PARP inhibitor progression. Clin Cancer Res. 2023;29(18):3706–16.

CAS  PubMed  PubMed Central  Google Scholar 

Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, et al. BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 2019;9(2):210–9.

CAS  PubMed  Google Scholar 

Rusan M, Andersen RF, Jakobsen A, Steffensen KD. Circulating HOXA9-methylated tumour DNA: a novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer. Eur J Cancer. 2020;125:121–9.

CAS